Bharat Parenterals Ltd.
Snapshot View

359.15 +17.10 ▲5.0%

20 May 2022, 04:01:00 PM
Volume: 4,964

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.bplindia.in
Market Cap 207.40 Cr.
Enterprise Value(EV) 216.63 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 32.73 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 10.97 Trailing Twelve Months Ending 2021-12
Industry PE 29.26 Trailing Twelve Months Ending 2021-12
Book Value / Share 278.32 Trailing Twelve Months Ending 2021-12
Price to Book Value 1.29 Calculated using Price: 359.15
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 0.58 Cr. 5,774,666 Shares
FaceValue 10
Company Profile

Bharat Parenterals was formed under the chairmanship of Ramesh Desai and incorporated as limited company on September 3, 1992. The company has grown steadily from a humble beginning, to a position of strength under the stewardship of Bharat R. Desai, a visionary whose untiring patience, perseverance & unflinching commitment has resulted in the growth of the company. He has effectively combined his tact & talent, business acumen & professional experience in the pharmaceutical field to bring the company in the forefront of contract manufacturing units in Gujarat. Besides, the company has established its own range of products in domestic & international markets. The company has added a feather in the cap by setting up a dedicated facility for antiretroviral drugs to its existing facility of general & B-Iactum group of drugs.

The company has established its own range of products in domestic & international markets. Its main vision is commited to become a major pharmaceutical company catering to domestic and international market by manufacturing and marketing high quality Pharmaceutical Formulation meeting all customer & regulatory requirements. 

Business area of the company:

The company is engaged in to the business of the Pharmaceuticals & Drugs.

Products:

GENERAL:

- Tablets 

- Capsules

- Injections

- Oral Liquids 

 - Dry Syrups

- External Preparations

- ENT

- Sachets 

- Granules

LACTAM:

- Tablets 

- Capsules 

- Injections 

- Dry Syrups

CEPHALOSPORINS:

- Tablets  

- Capsules

- Injections 

- Dry Syrups

 - Sachets

ANTIRETROVIRAL:

- Tablets

- Capsules 

- Oral Liquids

VETERINARY:

- Tablets

- Injections 

- Oral Liquids

- Semi Solids

Subsidiaries:

Varenyam (A division of Bharat Parenterals).

The company was formed under the chairmanship of Mr. Bharat Desai and incorporated as Private Limited company on 9th July 2016.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+5.00%
1 Week
+15.22%
1 Month
-1.63%
3 Month
+7.39%
6 Month
-2.31%
1 Year
-7.69%
2 Year
+74.64%
5 Year
10 Year
6 years 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 11.38 11.45 13.35 25.47 22.76 15.53
Return on Capital Employed (%) 14.23 11.47 18.10 39.30 30.83 20.24
Return on Assets (%) 5.37 5.99 7.61 14.71 13.94 10.52

Balance Sheet View Details

Particulars 7 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 57 64 73 94 118 144 160
Non Curr. Liab. 7 3 0 4 3 11 10
Curr. Liab. 56 43 57 61 66 44 52
Minority Int. 0 4
Equity & Liab. 120 110 130 159 188 199 227
Non Curr. Assets 49 46 39 41 56 51 58
Curr. Assets 72 64 91 118 132 148 169
Misc. Exp. not W/O
Total Assets 120 110 130 159 188 199 227

Profit Loss View Details

Particulars 7 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 124 111 137 220 228 205 200
Other Income 5 8 7 13 12 9 7
Total Income 129 119 144 232 240 213 207
Total Expenditure -114 -105 -124 -191 -201 -179 -174
PBIDT 15 14 19 42 40 34 33
Interest -1 -1 -1 -1 -1 -1 -1
Depreciation -4 -6 -6 -6 -6 -6 -7
Taxation -3 -1 -4 -13 -9 -7 -7
Exceptional Items
PAT 6 7 9 21 24 20 19
Minority Interest 0 0
Share Associate
Other Related Items
Consolidated Net Profit 6 7 9 21 24 20 19
Adjusted EPS 11 12 16 37 42 36 33

Cash Flow View Details

Particulars 6 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. -2 6 20 14 31
Cash Fr. Inv. -2 -8 -9 -13 -48
Cash Fr. Finan. -8 4 -4 -3 8
Net Change -11 2 7 -1 -8
Cash & Cash Eqvt 2 4 11 10 2

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 74.42 74.42 74.42 74.42 74.42 74.42 74.42 74.42 73.84
Public 25.58 25.58 25.58 25.58 25.58 25.58 25.58 25.58 26.16
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Mon, 16 May 2022
Board Meeting Intimation for Intimation Of Meeting Of Board Of Directors For Approval Of Audited Financial Results For The Quarter And Year Ended 31St March 2022.
Bharat Parenterals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2022 inter alia to consider and approve 1. The Audited financial results of the Company for the Quarter and year ended on March 31 20222. re-appointment of M/s CNK & Associates LLP Chartered Accountant(FRN 101961W) as Statutory Auditor of the company
Mon, 09 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company Bharat Parenterals Ltd
2 CIN NO. L24231GJ1992PLC018237
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2021-22 2022-23
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)2020-21 2021-22
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-LUBHANSHI JHALANI
Designation :-COMPANY SECRETARY
Name of the Chief Financial Officer :- JIGNESH SHAH
Designation : -CFO

Date: 09/05/2022

Thu, 21 Apr 2022
Certificate Under Regulation 40(9) Of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015 For The Year Ended 31St March 2022
With reference to the captioned subject we enclose herewith Certificate under Regulation 40(9) of SEBI (Listing Obligation & Disclosure Requirements) Regulation 2015 for the year ended 31st March 2022 issued by CS Niraj Trivedi Practicing Company Secretary Vadodara.We request you to kindly take the same on record.

Technical Scans View Details

Fri, 20 May 2022
Higher Delivery Quantity Higher Delivery Quantity
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity
Close Crossing Last Week High Close Crossing Last Week High
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 219,659.12 915.50 +3.5%
Divi's Laboratories Ltd. 114,020.08 4,295.05 +2.2%
Cipla Ltd. 78,954.82 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. 70,669.41 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. 52,783.35 3,671.00 +1.0%
Gland Pharma Ltd. 50,388.39 3,061.70 -1.1%
Piramal Enterprises Ltd. 45,754.22 1,917.10 +1.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 34.09 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 44.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 31.37 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 32.38 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 46.57 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 41.59 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 36.83 1,917.10 +1.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.25 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-12 10.53 4,295.05 +2.2%
Cipla Ltd. Consolidated 2022-03 3.79 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 3.68 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.54 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2022-03 7.04 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-12 1.29 1,917.10 +1.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 0.10 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 14.13 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,917.10 +1.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,917.10 +1.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 915.50 +3.5%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,295.05 +2.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 978.60 +4.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,246.30 +8.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,671.00 +1.0%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,061.70 -1.1%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,917.10 +1.2%